Diligence memo · auto-generated · as of July 2, 2026
Unite Genomics, Inc.
Unite Genomics, Inc. looks under-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
Unite Genomics, Inc. operates in Biotech, based in San Mateo.
Sub-sector tags: biotech.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Unite Genomics, Inc. has raised $7.8M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $5.8M on 2018-11-21.
Most recent recorded round closed around 2023-10-11.
Valuation (modeled)modeled
Provath models Unite Genomics, Inc. at approximately $15M (range $2.2M–$38M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.29× the median modeled value of Series A Biotech companies in 2022–2024 (12 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 59 months.
Last raise 2.7 yr ago; this sector typically re-raises about every 11 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round was 2.9× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 84% of Biotech peers (233 compared).
Modeled value ranks above 76% of those peers.
Closest niche peers: Epsilon3, Inc., Salish Bioscience Inc., HB Biotech, Inc., Acoustic Wave Cell Therapy, Inc., Mindstate Design Labs, Inc..
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.